Results 171 to 180 of about 23,896 (206)
Some of the next articles are maybe not open access.
Biological treatment is approved for severe eosinophilic asthma
BMJ, 2016Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1 The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list ...
openaire +2 more sources
Eosinophilic and noneosinophilic asthma: Beyond severe asthma
2023Tara F. Carr, Sanjay B. Patel
openaire +1 more source
Primary lysis of eosinophils in severe desquamative asthma
Clinical & Experimental Allergy, 2014SummaryPrimary lysis of eosinophils liberates free eosinophil granules (FEGs) releasing toxic proteins in association with bronchial epithelial injury repair. Eosinophil lysis may be significantly pathogenic. Bronchial mucosal FEGs are associated with uncontrolled asthma, severe asthma, aspirin‐sensitive asthma, and lethal asthma. FEGs in the bronchial
openaire +2 more sources
Emerging Therapies in Severe Eosinophilic Asthma
Archivos de Bronconeumología (English Edition), 2017Pee Hwee, Pang +1 more
openaire +2 more sources
The prevalence of severe asthma and severe eosinophilic asthma in Finland
Epidemiology, 2023Arja Viinanen +6 more
openaire +1 more source
BIOLOGICS SWITCH IN SEVERE EOSINOPHILIC ASTHMA
Airway pharmacology and treatment, 2021Caminati, Marco +11 more
openaire +1 more source
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
New England Journal of Medicine, 2021Andrew Menzies-Gow +2 more
exaly
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
New England Journal of Medicine, 2021Michael E Wechsler +2 more
exaly
Biologic Therapies for Severe Asthma
New England Journal of Medicine, 2022Guy G Brusselle, Gerard H Koppelman
exaly